Prevalence, Outcomes, and Management of Ventricular Arrhythmias in COVID-19 Patients.

We review the current data on epidemiology, the clinical significance, the pathophysiologic mechanisms, and the treatment of VAs in the setting of COVID-19. VAs prevail in 0.15% to 8% of hospitalized patients, but only sustained and rapid tachyarrhythmias are purportedly associated with a significant increase in mortality. Multiple factors can elicit VAs, which are ultimately deemed to be a marker of severe systemic disease rather than a distinct cardiac condition. Even though the electrophysiologist plays a determinant role in the secondary prevention of VAs, a multidisciplinary approach is indispensable for primary prophylaxis and acute management.
Competing Interests: Disclosure Dr A. Natale has received speaker honoraria from Boston Scientific, Biosense Webster, St. Jude Medical, Biotronik, and Medtronic; and is a consultant for Biosense Webster, St. Jude Medical, and Janssen. Dr L. Di Biase is a consultant for Biosense Webster, RMG, Stereotaxis, Boston Scientific, and Abbott. Dr L. Di Biase received speaker honoraria/travel from Medtronic, Atricure, and Biotronik. All other authors have reported that they have no relationships relevant to the contents of this article to disclose.
(Copyright © 2021 Elsevier Inc. All rights reserved.)